# Actuate Therapeutics, Inc. Common stock (ACTU)

> Actuate Therapeutics, Inc. Common stock (ACTU) trades at $0.3351 (-9.68%) as of 7:57:24 PM EDT on Oct 30, 2026, -62.31% over the past month. Market cap is $8.05M, with 4.7 days to cover in short interest.

Canonical: https://massive.com/quote/actu
Data as of: 2026-10-30T23:57:24.808Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$0.3351** -0.04 (-9.68%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$0.3600** +0.02 (+7.43%)
As of 7:57:24 PM EDT on Oct 30, 2026 · After hours

## Stock performance

How Actuate Therapeutics, Inc. Common stock (ACTU) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -9.68% |
| 1W | -29.48% |
| 1M | -62.31% |
| YTD | -94.52% |
| 1Y | -95.00% |
| 52-wk range | $0.33 – $7.90 |

From daily closes through Oct 30, 2026.

## Key statistics

Today's trading snapshot for ACTU: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $0.33 – $0.39 |
| Open | $0.38 |
| Prev close | $0.37 |
| Volume | 489.47K |
| Market cap | $8.05M |
| Shares out | 24.01M |

## Valuation and profitability ratios

Valuation and profitability ratios for Actuate Therapeutics, Inc. Common stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 8.25 |
| P/FCF | — |
| ROE | -2067.8% |
| ROA | -393.4% |
| Debt/Equity | 0.04 |
| Div yield | 0.00% |

As of Oct 30, 2026

## Insider trading

[Actuate Therapeutics, Inc. Common stock (ACTU) insider trading](https://massive.com/quote/actu/insider-trading.md): open-market Form 4 buys and sells by Actuate Therapeutics, Inc. Common stock insiders over the last 12 months.

## 8-K filings

Material corporate events Actuate Therapeutics, Inc. Common stock has disclosed to the SEC on Form 8-K.

- Oct 30, 2026 · [Listing deficiency notice](https://massive.com/quote/sec-filings/8-k/delisting-notices.md)
  “On October 28, 2026, Actuate Therapeutics, Inc. received a written notice from The Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days, the bid price for the Company's common stock had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1).”
- Oct 28, 2026 · Public offering
  “The combined public offering price for each set of two shares of common stock and one accompanying Common Warrant to purchase one share of common stock is $0.71, before underwriting discounts and commissions. On October 28, 2026, the Company closed the Offering.”
- Jul 17, 2026 · [Listing deficiency notice](https://massive.com/quote/sec-filings/8-k/delisting-notices.md)
  “On July 15, 2026, Actuate Therapeutics, Inc. received a letter from the listing qualifications department staff of The Nasdaq Stock Market notifying the Company that from June 1, 2026 to July 14, 2026, the Company's Market Value of Listed Securities (MVLS) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days from the date of the Notice, or through January 11, 2027, to regain compliance with respect to the MVLS Requirement.”
- May 22, 2026 · Annual meeting results
  “At the Annual Meeting, the Company's stockholders (i) elected each of the two Class II director nominees listed below to the Company's Board of Directors, each to serve for a three-year term until the 2029 Annual Meeting of Stockholders, and until their respective successors are duly elected and qualified; and (ii) ratified the appointment of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
- May 11, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “On May 11, 2026, Actuate Therapeutics, Inc. (the "Company") issued a press release announcing FDA clearance of an Investigational New Drug ("IND") application to conduct a Phase 1/2 study and future plans to advance the elraglusib development program.”

## ACTU short interest

How heavily ACTU is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 4.7 |
| Short interest | 1.87M |
| Avg volume | 396.89K |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## ACTU news

The latest news and headlines about Actuate Therapeutics, Inc. Common stock (ACTU).

- [Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering](https://www.globenewswire.com/news-release/2026/10/27/3388899/0/en/actuate-therapeutics-announces-pricing-of-11-0-million-underwritten-public-offering.html) · GlobeNewswire Inc. · Oct 27, 2026 · neutral sentiment
- [AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer](https://www.zacks.com/stock/news/3003008/abbvie-s-temab-a-gets-two-fda-breakthrough-therapy-tags-in-cancer?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-3003008) · Zacks Investment Research · Oct 8, 2026 · positive sentiment
- [Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer](https://www.globenewswire.com/news-release/2026/06/01/3304175/0/en/Actuate-Therapeutics-Announces-ASCO-Poster-Presentations-Demonstrating-Compelling-Clinical-and-Biomarker-Data-for-Elraglusib-in-First-Line-Metastatic-Pancreatic-Cancer.html) · GlobeNewswire Inc. · Jun 1, 2026 · positive sentiment
- [Actuate Therapeutics to Present at The Citizens Life Sciences Conference](https://www.globenewswire.com/news-release/2026/03/04/3249771/0/en/Actuate-Therapeutics-to-Present-at-The-Citizens-Life-Sciences-Conference.html) · GlobeNewswire Inc. · Mar 4, 2026 · positive sentiment
- [Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option](https://www.benzinga.com/pressreleases/25/09/g47631468/actuate-therapeutics-announces-closing-of-17-25-million-public-offering-of-common-stock-including-) · Benzinga · Sep 11, 2025 · neutral sentiment

## About Actuate Therapeutics, Inc. Common stock

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 12 |
| Listed | Aug 13, 2024 |

[Company website](https://www.actuatetherapeutics.com)

## FAQ

### What is the Actuate Therapeutics, Inc. Common stock (ACTU) stock price today?

Actuate Therapeutics, Inc. Common stock (ACTU) is trading at $0.3351 (-9.68% on the day) as of 7:57:24 PM EDT on Oct 30, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Actuate Therapeutics, Inc. Common stock?

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3).

### What is the short interest in ACTU?

As of Oct 15, 2026, ACTU has 1.87M shares short and 4.7 days to cover.

### What exchange is ACTU listed on?

Actuate Therapeutics, Inc. Common stock (ACTU) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time ACTU quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=ACTU`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Actuate Therapeutics, Inc. Common stock (ACTU) insider trading](https://massive.com/quote/actu/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms